GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Price-to-Free-Cash-Flow

Virax Biolabs Group (Virax Biolabs Group) Price-to-Free-Cash-Flow : N/A (As of Jun. 10, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Price-to-Free-Cash-Flow?

As of today (2024-06-10), Virax Biolabs Group's share price is $1.97. Virax Biolabs Group's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-24.62. Hence, Virax Biolabs Group's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Virax Biolabs Group's Price-to-Free-Cash-Flow or its related term are showing as below:

VRAX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.56
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Virax Biolabs Group's Free Cash Flow per Share for the six months ended in Sep. 2023 was $-23.40. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-24.62.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -46.30% per year.

During the past 4 years, Virax Biolabs Group's highest 3-Year average Free Cash Flow per Share Growth Rate was -46.30% per year. The lowest was -46.30% per year. And the median was -46.30% per year.


Virax Biolabs Group Price-to-Free-Cash-Flow Historical Data

The historical data trend for Virax Biolabs Group's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Price-to-Free-Cash-Flow Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
- - - -

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of Virax Biolabs Group's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Virax Biolabs Group's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Price-to-Free-Cash-Flow falls into.



Virax Biolabs Group Price-to-Free-Cash-Flow Calculation

Virax Biolabs Group's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.97/-24.615
=N/A

Virax Biolabs Group's Share Price of today is $1.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-24.62.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Virax Biolabs Group  (NAS:VRAX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Virax Biolabs Group Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.